Pharmadrug (TSE:PHRX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmaDrug has commenced a clinical study for PD-001, a patented enteric-coated cepharanthine, aimed at treating viral infections. The study will assess bioavailability and pharmacokinetics in volunteers, with the goal to improve upon the drug’s traditionally low bioavailability. Positive results could lead to Phase 2 trials and attract potential pharmaceutical partners or investors.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money